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adverse events were observed in 39% of pts; most frequently 
nausea (6%), diarrhea, dizziness, and rash (4% each). 
Dyspnea, syncope, raised GGT and sepsis (each 5%) were the 
most common grade ≥3  AEs. Among 29 evaluable HNSCC pts 
for efficacy, 4 pts had a partial response. Numerous anti-PD-
1/PD-L1 agents are currently tested in HNSCC. First 
randomized trial with nivolumab vs standard of care in 
second line after platinum based first line therapy has just 
closed. Randomized trials testing pembrolizumab and 
durvalumab in first-line or second-line treatment for R/M 
HNSCC patients are ongoing. Beside evaluation of efficacy, 
these studies should help define the best population (HPV 
status, prior therapies) and more useful biomarkers than 
threshold of PD-L1 expression, to select patients who can 
benefit from these new agents. Flare-up reaction with 
increase of tumor volume and immune-related adverse 
events may occur: new guidelines are needed to define 
criteria of response, time to stop treatment and management 
of toxicities. Some patients may have a fast progression 
under monotherapy and mechanisms of resistance are 
unclear. New approaches combining anti-PD-L1/PD-1 agents 
and other immune-modulators, chemotherapy and 
radiotherapy are currently explored. Abscopal effect related 
to anti-PD-L1/PD-1 agents seems promising. For locally 
advanced HNSCC, trials testing combinations with anti-PD-
L1/PD-1 agents in induction regimen and concurrent CRT are 
ongoing. The story of immunotherapy as a new paradigm in 
HNSCC is just beginning… 
 
SP-0410  
Proton therapy in HNSCC: better than IMRT?  
C. Rasch1 
1Academic Medical Center, Department of Radiation 
Oncology, Amsterdam, The Netherlands 
 
Abstract not received 
 
 
Symposium: SBRT in lung - choices and their impact on 




Dosimetric aspects and robustness in treatment plan 
optimisation of small tumours 
A. Ahnesjö




Stereotactic radiation of small brain targets provides high 
spatial resolution and accuracy for positioning of patient and 
radiation fields, almost on submillimeter ranges. This is not 
matched by equally sharp dose gradients, since finite source 
size, collimator design limitations and transport of electrons 
in the irradiated tissue all diffuses the dose. Not surprisingly, 
the dose prescriptions evolving for small brain tumors aimed 
for a specified dose to the target periphery, accepting 
whatever resulting dose to the target center. A kind of 
standard evolved aiming for a ratio of approximately 65% 
relative dose at the periphery versus the maximum target 
center dose (or 154% center-to-periphery ratio). This dose 
heterogeneity was considered favorable, as to more 
effectively treat presumably hypoxic cells at the tumor 
center. The stereotactic treatment methodology for brain 
treatments were in the early 1990s transferred to radiation 
of liver metastasis. Through use of stereotactic body frame 
high target positioning reproducibility was achieved, and 
similar dose prescriptions of heterogeneous dose were 
applied, with a center-to-periphery dose ratio of 
approximately 154%. Soon the technique was also applied to 
peripheral lung tumors.  
Following the development of 3D treatment planning systems 
in the late 1980s, ICRU responded to the need for consistent 
handling of geometrical uncertainties and launched in 1993 
the ICRU 50 report recommending the use of GTV, CTV and 
PTV to capture the uncertainties. Specifically, the role of 
PTV was to “ensure that the prescribed dose is actually 
absorbed in the CTV”. The normal use of the PTV is to plan a 
homogenous dose to its interior, through which it is assumed 
that the CTV gets the same dose as it is located in the PTV. 
This requires the dose inside the PTV to be both 
homogeneous and robust with respect to movements 
involving heterogeneities. The PTV concept was applied also 
for extracranial stereotactic body treatments, often 
inheriting a high center-to-periphery prescription. Dose 
calculations at the time used “class a” algorithms that not 
account for dose variations due to a varying level of lateral 
charged particle equilibrium caused by low density regions. 
Most so called pencil beam algorithms belong to this, class a, 
category. Accurate dose calculations can now be achieved 
with “class b” algorithms such as Monte Carlo, Collapsed 
Cone or Grid based Boltzmann equation solvers. However, for 
any algorithm that would calculate the dose physically 
correct, the resulting dose for the PTV is not representative 
for the CTV when the margin around the latter contains a 
lower density medium. Hence, the straight forward 
application of PTV based treated planning together with 
heterogeneous prescriptions principles (originally inherited 
from intracranial treatments), has created a confused 
situation with large uncertainties with respect to the actually 
delivered doses.  
A robust dosimetry can be achieved by realizing that the dose 
to a CTV surrounded by a low density medium will be 
independent of movements as long as it is exposed to a 
uniform fluence. Given that a near homogeneous fluence 
cover the PTV, dose prescriptions can then be done directly 
to the CTV based on a dose calculation with a “class b” 
algorithm (MC, CC or equivalent). As long as the movements 
of the CTV are kept well inside a PTV with a homogeneous 
fluence, the dose delivered to the CTV will be much closer to 
the prescribed dose, thus providing robust dose specification 
for small tumors. However, tools for optimization of uniform 
fluence are presently not provided in clinical TPS. Luckily, 
several workarounds exists that can “cheat” the optimization 
of homogenous dose to instead yield a effectively 
homogeneous fluence. From a pure physics point of view, this 
can be achieved by incapacitating the lateral spread of 
energy from the rays of the primary beam. In class a 
algorithms of the pencil beam kind, this can be implemented 
by changing the pencil beam parameter controlling the 
lateral spread. In point kernel algorithms such as CC, similar 
manipulation of kernel data can be done. In essence, in most 
algorithms fluence is a precursor for dose providing 
opportunities to access it. Alternatively, the density of the 
PTV can be set to a high value that shortens the electron 
transport distance enough to make the dose more fluence 
like.  
In summary, a robust small lung tumor dose can be 
implemented through a planning process in which the PTV is 
determined by the common practice addition of a setup 
margin to a MIP projections ITV, but replacing the common 
practice dose calculations by a fluence optimization followed 
by a class b dose calculation with the CC (or similar) 
algorithm, using absolute dose prescriptions to the CTV 
rather than the PTV. For a test series of 5 patients this 
procedure reduced the difference between prescribed and 
delivered dose to the CTV from 30% to 8% in D98, with a 
similar reduction for D02. 
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The current practice of cranial and extra-cranial stereotactic 
radiotherapy is in many ways influenced by Gamma-Knife 
Radiosurgery (GN-RS). It has been a key component of GN-RS 
to treat the target volumes without any safety margins (GTV 
= PTV) and to use inhomogeneous dose profiles within the 
target volume. The dose was most frequently prescribed to a 
low isodose e.g. 50% meaning that substantially higher doses 
are delivered to the central part of the tumor.  
This practice of dose prescription to a low target 
encompassing isodose line has been adopted in extra-cranial 
stereotactic radiotherapy (Stereotactic Body Radiotherapy 
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SBRT) despite many differences to GN-RF: (1) safety margins 
are used in almost all SBRT indications; (2) in lung SBRT, the 
use of safety margins will result in inclusion of low density 
lung tissue into the target volume; (3) radiotherapy delivery 
is today performed using MLC and in many centers intensity-
modulated techniques allowing more sophisticated dose 
shaping; (4) target and organs at risk motion will affect the 
delivered dose profile as compared the planned dose profile; 
(5) the composition of the taget volumes in SBRT is very 
different to GN-RS - Organs-at-risk are not only close by but 
within the target volume; (6) in the RTOG protocols of SBRT 
for stage I NSCLC, dose prescription to a wide range of 
isodose lines is allowed.  
Based on these differences between GN-RS and SBRT above, 
it is obvious that the concept of dose prescription to a fixed 
isodose line is not sufficient for SBRT practice. The dose 
profile within the target volume needs to be sufficiently 
prescribed and reported to achieve better standardization 
and comparability between institutions, studies and 
individual patients. Additionally, current SBRT technology 
allows to adapt the dose profile within the PTV to the 
patient-specific clinical requirements: homogeneous dose 
profiles or even cold spots might allow organ at risk sparing; 
in contrast, an escalation of the dose within the target 
center might be beneficial for targets without critical normal 
tissue within the PTV. Recommendations by the ICRU specific 
for the needs of SBRT are eagerly awaited and future studies 
will better define how to optimize SBRT dose planning. 
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In curative SBRT regimen, few large doses per fraction are 
applied in a highly conformal way. Such protocols, however, 
usually do not only differ from conventional protocols in the 
size of the dose per fraction, but also with regard to overall 
treatment time and total (equieffective) dose. Moreover, 
large doses per fraction are usually administered to (normal 
tissue) volumes that are clearly smaller compared to 
conventional protocols. Hence, all these parameters, i.e. 
recovery, repopulation, tumour reoxygenation and normal 
tissue volume effects, need to be included into 
considerations concerning the biological effect of SBRT 
protocols – independently for tumor, early and late 
responding tissues.  
The effect of dose per fraction (“recovery”) for tumors is – 
with few exceptions – considered as low, as expressed by a 
high a/b-value in the linear-quadratic (LQ) model. Recently, 
a high fractionation effect was shown for prostate and breast 
tumors, and is also discussed for others. For lung tumours, 
however, a small capacity for recovery can be assumed. Early 
responding normal tissues usually display a similarly low 
fractionation effect, while most late radiation effects have a 
high sensitivity with regard to changes in dose per fraction. 
Hence, doses per fraction must be adjusted to the respective 
tumor type and the expected (late) morbidity pattern in 
order to achieve the biologically equieffective doses that 
result in optimum dissociation between treatment efficacy 
and adverse events.  
The linear-quadratic model has been shown to only 
inadequately describe the effect of large doses per fraction 
(>6-10 Gy) for cell survival endpoints in vitro (colony forming 
assay) and in vivo (e.g. intestinal crypt survival assay). Here, 
the LQ model overestimates the effects of exposure in the 
high-dose region. It needs to be emphasized, however, that 
in the vast majority of pre-clinical investigations and analyses 
of the fractionation effect for morphological and functional 
endpoints, large doses per fraction and/or single doses were 
regularly included. In clear contrast to the cell survival based 
analyses, these studies in general do not show any major 
difference of the fit of the LQ model for the in- or exclusion 
of large doses per fraction in the analyses. Moreover, no 
deviation of the resulting a/b-values from the respective 
estimates from clinical data was observed. This indicates the 
applicability of the LQ model also for the calculation of 
equieffective doses at high doses per fraction, such as 
applied in SBRT protocols in the lung. Besides high dose per 
fraction,  
SBRT protocols regularly include a shortening of the overall 
treatment time (OTT) compared to conventional or 
moderately hypofractionated protocols. This is associated 
with less tumour repopulation, which also contributes to the 
increased tumor effectiveness. With very few fractions in 
short time intervals, however, tumour reoxygenation may 
also be less effective, thus at least partly counteracting the 
benefit of the shorter OTT. It also needs to be noted that 
SBRT protocols with short OTT are less permissive for 
regenerative processes in early responding normal tissues. 
These protocols hence also bear a risk of increased early 
normal tissue reactions and thus, in certain tissues, of 
enhanced (“consequential”) late effects.  
The administration of large doses per fraction and large total 
doses is mainly facilitated by a strong conformation of the 
high-dose volume to the target, i. e. a minimization of the 
normal tissue volumes exposed to these doses, and is 
associated with very steep dose gradients within the adjacent 
normal tissues. However, it must be emphasized that in such 
scenarios, not only the amount of normal tissue effects may 
be changed, but also their quality, with altered tissue 
pathophysiology and morbidity endpoints that are usually not 
observed with conventional or moderately hypofractionated 
protocols. Prominent examples are the manifestation of 
atrophic rather than fibrotic processes, or pathologic rib 
fractures in SBRT of peripheral lung tumors.  
In conclusion, administration of large doses per fraction in 
SBRT may be advantageous for biological reasons. Estimation 
of biologically equieffective doses may be based on the 
standard LQ model. However, such treatment strategies not 
only impact on tissue recovery, but can also affect other 
radiobiological parameters (radiopathology, repopulation, 
volume effects) in a complex manner. Therefore, the 
patients included in such therapeutic protocols need to be 
monitored carefully not only for treatment outcome, but also 
for treatment-related morbidity. 
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Purpose or Objective: 4DCT-ventilation is an exciting new 
lung function imaging modality that uses 4DCT data to 
calculate lung function maps (Fig 1).  
 
 
